Women Have Lower Mortality Than Men at One Year After TAVR

Share this content:
Women Have Lower Mortality Than Men at One Year After TAVR
Women Have Lower Mortality Than Men at One Year After TAVR

WEDNESDAY, Feb. 24, 2016 (HealthDay News) -- For patients undergoing transcatheter aortic valve replacement (TAVR), women have lower mortality than men at one year, according to a study published online Feb. 23 in the Annals of Internal Medicine.

Susheel Kodali, M.D., from the Columbia University Medical Center in New York City, and colleagues examined sex-specific differences in patients undergoing TAVR in the Placement of Aortic Transcatheter Valves (PARTNER) trial. Data were included for 1,220 women and 1,339 men who were considered high-risk and inoperable.

The researchers found that women had lower rates of hyperlipidemia, diabetes, smoking, and renal disease at baseline, but higher Society of Thoracic Surgeons Predicted Risk of Mortality scores (11.9 versus 11.1 percent; P < 0.001). Women had more vascular complications (P < 0.001) and major bleeding (P = 0.012) after TAVR, but less frequent moderate and severe paravalvular regurgitation (P < 0.001). The unadjusted all-cause mortality rate and stroke incidence at 30 days were similar (P = 0.52 and 0.28, respectively). All-cause mortality was significantly lower for women than men at one year (hazard ratio, 0.72; 95 percent confidence interval, 0.61 to 0.85).

"Sex-specific risk in TAVR is the opposite of that in surgical aortic valve replacement, for which female sex has been shown to be independently associated with an adverse prognosis," the authors write.

Several authors disclosed financial ties to pharmaceutical and medical device companies, including Edwards Lifesciences, which funded the PARTNER trial.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths